Ribo Newsroom
-
Ribo Launches Automated Intelligent Drug Screening Center to Advance siRNA+AI Drug DiscoveryRibo Launches Automated Intelligent Drug Screening Center to Advance siRNA+AI Drug DiscoverySeptember 22, 2026 -
Ribo Officially Integrated into Stock Connect Southbound Trading Link, Embarking on a New Chapter in Capital MarketsRibo Officially Integrated into Stock Connect Southbound Trading Link, Embarking on a New Chapter in Capital MarketsSeptember 7, 2026 -
Ribo Presented New Data Highlighting Triglycerides, ApoC3 and Cardiovascular Health at ESC 2026Ribo Presented New Data Highlighting Triglycerides, ApoC3 and Cardiovascular Health at ESC 2026August 31, 2026 -
Ribo Included in HSCI, Set to Become Stock Connect Southbound Eligible Investment TargetRibo Included in HSCI, Set to Become Stock Connect Southbound Eligible Investment TargetAugust 21, 2026 -
Ribo Discloses Positive Data from Vortosiran Phase IIa Trial - World’s First Clinical Data on siRNA-Mediated FXI Inhibition Following Multiple Dosing in Patients with Coronary Artery DiseaseRibo Discloses Positive Data from Vortosiran Phase IIa Trial - World’s First Clinical Data on siRNA-Mediated FXI Inhibition Following Multiple Dosing in Patients with Coronary Artery DiseaseJuly 22, 2026 -
Breaking Preview: Ribo to Unveil Global First Phase IIa Clinical Data of Lead Asset Vortosiran at CPIC, Followed by Dedicated Data Briefing with Live StreamingRibo will present at the inaugural CPIC on July 22, where it will disclose for the first time Phase IIa clinical data of vortosiran (RBD4059) for CAD.July 8, 2026